However, a similar pattern of DAT decline in the sPD group suggests that LRRK2 G2019S carriers may be good candidates for investigating striatal dopaminergic dysfunction and nervous adaptation in the premotor stage of PD32,38. This evidence concerns the gene SLC6A3 and Platelet storage pool disease.